H.C. Wainwright raised the firm’s price target on Replimune (REPL) to $22 from $21 and keeps a Buy rating on the shares. The firm expects a relatively uneventful FDA review process for RP1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Navigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global Risks
- Replimune price target raised to $19 from $16 at Wedbush
- Replimune price target raised to $21 from $18 at Leerink
- Replimune reports Q3 EPS (79c) vs (77c) last year
- Replimune Group (REPL) Q3 Earnings Cheat Sheet